Country: Tanzania
Language: English
Source: Tanzania Medicinces & Medical Devices Authority
Bicalutamide
Intas Pharmaceuticals Limited, INDIA
Hormone antagonists and related agents?
Bicalutamide
50
Tablets
Intas Pharmaceuticals Limited, INDIA
Physical description: White to off white, round, biconvex, film-coated tablets debossed 'B 50' on one side and plain on other side; Local technical representative: MURJI BROTHERS (8448)
Registered/Compliant
2021-06-03
TMDA/DMC/MRE/F/016 Revision# TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY PUBLIC ASSESSMENT REPORT FOR INTAS (BICALUTAMIDE 50MG) FILM COATED TABLETS VERSION NUMBER 1.0 14 TH APRIL, 2022 P. O. Box 77150, EPI Mabibo, Off Mandela Road, Dar es Salaam, Tanzania Tel: +255-22-2450512/2450751/ 2452108; Fax: +255-22-2450793 Email: info@tmda.go.tz; Website: mwww.tmda.go.tz TANZANIA PUBLIC ASSESSMENT REPORT _TMDA/DMC/MRE/F/016 _ _REV #:_ 1. INTRODUCTION INTAS Bicalutamide is a generic medicine of CASODEX® of AstraZeneca. INTAS Bicalutamide is an anticancer medicine belonging to Antineoplastic and Immunomodulating Agents, Anti- androgens group. INTAS Bicalutamide exerts is activity by binding to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. INTAS Bicalutamide is approved in Tanzania for use in adults and elderly. 1.1 PRODUCT DETAILS Registration number TAN 21 HM 0214 Brand name INTAS Bicalutamide Generic name, strength and form Bicalutamide 50 mg film coated tablets ATC classification ATC code L02BB03 Anti-androgens Distribution category POM Country of origin India Associated product NA Marketing Authorization Holder Intas Pharmaceuticals Limited Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380054, Gujarat, INDIA. Telephone: +9179 39837909 Email: alkesh_shah@intaspharma.com Local Technical Representative Lifeline Pharmacy Ltd Plot no. 540, Kalenga Street, Upanga, P.O. BOX 76969, Dar esSalaam, TANZANIA. Telephone: (255) 713244004 Email: lifelineupanga@gmail.com 1.2 ASSESSMENT PROCEDURE The application for registration of INTAS Bicalutamide was submitted on 10 th October, 2018. The product underwent joint EAC assessment. Assessment was completed in 2 rounds of evaluation. INTAS Bicalutamide was registered on <03 rd June 2021 1.3 INFORMATION FOR USERS Visual description of the finished product White to off white, round, biconvex, film coated tablets debossed ‘B 50’ on one side and plain on other side. Primary packing material Clear PVC/PVdC-Alu bl Read the complete document